There are 2949 resources available
729P - Prognostic value of PD-L1 status in the primary lesion as a risk factor for developing metastatic disease in localized renal cell carcinoma: A subgroup analysis of the ARCHERY study
Presenter: Masahiro Nozawa
Session: E-Poster Display
Resources:
Abstract
730P - Interim analysis of CASSIOPE: A real-world study of cabozantinib for the treatment of advanced renal cell carcinoma (aRCC) after VEGF-targeted therapy in Europe
Presenter: Giuseppe Procopio
Session: E-Poster Display
Resources:
Abstract
731P - The impact of proton pump inhibitors on pazopanib exposure
Presenter: Stefanie Krens
Session: E-Poster Display
Resources:
Abstract
732P - Cabozantinib in non-clear cell metastatic renal cell carcinoma and sarcomatoid renal cell carcinoma: Real-world data from the CABOREAL study
Presenter: Aude Fléchon
Session: E-Poster Display
Resources:
Abstract
733P - Quality of life assessment in renal cell carcinoma phase II and III clinical trials published between 2010 and 2020
Presenter: Veronica Mollica
Session: E-Poster Display
Resources:
Abstract
734P - Kidney manifestations in patients with hereditary leiomyomatosis and renal cell cancer syndrome (LHRCC) in Spain
Presenter: Ana Beatriz Sanchez
Session: E-Poster Display
Resources:
Abstract
735P - Metastatic renal medullary and collecting duct carcinoma in the era of antiangiogenic and immune checkpoint inhibitors: A multicentric retrospective study
Presenter: Zoé Guillaume
Session: E-Poster Display
Resources:
Abstract
736P - Updated data on patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sorafenib (SOR) vs observation (obs) after radical metastasectomy in the RESORT trial
Presenter: Giuseppe Procopio
Session: E-Poster Display
Resources:
Abstract
737P - Synchronous metastatic renal cell carcinoma (mRCC) treated with nivolumab and ipilimumab (N+I) and the primary tumour (PT) in place
Presenter: Aafke Meerveld-Eggink
Session: E-Poster Display
Resources:
Abstract
738P - Soluble PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTN2A1 as predictive biomarkers of nivolumab response in patients with metastatic clear cell renal carcinoma
Presenter: Lorena Incorvaia
Session: E-Poster Display
Resources:
Abstract